Anúncio
Anúncio

NRIX

NRIX logo

Nurix Therapeutics, Inc. Common stock

19.30
USD
Patrocinado
+0.66
+3.56%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pré-Mercado

19.33

+0.03
+0.16%

Relatórios de Lucros NRIX

Rácio de surpresa positiva

NRIX separação 9 de 21 últimas estimativas.

43%

Próximo Relatório

Data do Próximo Relatório
26 de jan. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$14.60M
/
-$0.90
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+84.89%
/
-12.62%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+9.87%
/
+20.00%

Nurix Therapeutics, Inc. Common stock earnings per share and revenue

On 09 de out. de 2025, NRIX reported earnings of -1.03 USD per share (EPS) for Q3 25, missing the estimate of -0.85 USD, resulting in a -20.05% surprise. Revenue reached 7.89 milhão, compared to an expected 17.07 milhão, with a -53.76% difference. The market reacted with a -10.13% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 19 analistas forecast an EPS of -0.90 USD, with revenue projected to reach 14.60 milhão USD, implying an diminuir of -12.62% EPS, and aumentar of 84.89% in Revenue from the last quarter.
FAQ
For Q3 2025, Nurix Therapeutics, Inc. Common stock reported EPS of -$1.03, missing estimates by -20.05%, and revenue of $7.89M, -53.76% below expectations.
The stock price moved down -10.13%, changed from $10.86 before the earnings release to $9.76 the day after.
The next earning report is scheduled for 26 de jan. de 2026.
Based on 19 analistas, Nurix Therapeutics, Inc. Common stock is expected to report EPS of -$0.90 and revenue of $14.60M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio